2-Benzyloxycarbonylamino-4-hydroxy-butyric acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Benzyloxycarbonylamino-4-hydroxy-butyric acid
• 英文别名: Cbz-DL-homoserine；4-hydroxy-2-(phenylmethoxycarbonylamino)butanoic acid
• 化学式: C₁₂H₁₅NO₅
• 分子量: 253.255
• InChiKey: UBXPAGGJJMSWLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-Benzyloxycarbonylamino-4-hydroxy-butyric acid 在 caesium carbonate 作用下， 生成 n=3
  参考文献：
  名称：

  Solid-phase synthesis of a naturally occurring β-(1→5)-linked d-galactofuranosyl heptamer containing the artificial linkage arm L-homoserine

  摘要：

  DOI：

  10.1016/s0040-4039(00)96948-x
• 作为产物：
  描述：

  DL-高丝氨酸 、 氯甲酸苄酯 以90%的产率得到2-Benzyloxycarbonylamino-4-hydroxy-butyric acid
  参考文献：
  名称：

  Solid-phase synthesis of a naturally occurring β-(1→5)-linked d-galactofuranosyl heptamer containing the artificial linkage arm L-homoserine

  摘要：

  DOI：

  10.1016/s0040-4039(00)96948-x

文献信息

• [EN] PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'ACIDE PHOSPHONIQUE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2Y12
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009069100A1

  公开（公告）日：2009-06-04

  The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I).

  这项发明涉及含有膦酸基团的2-苯基嘧啶衍生物，以及它们作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏-、肝脏和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的疾病或状况中的使用，包括人类和其他哺乳动物中的血栓形成。（I）。
• SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES
  申请人：Caroff Eva

  公开号：US20110046089A1

  公开（公告）日：2011-02-24

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 4 , R 5 , R a , R b , n, W and Z are as defined in the application, their preparation and their use as P2Y 12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及式I化合物的制备及其用途，式中R1、R2、R4、R5、Ra、Rb、n、W和Z的定义如申请中所述，以及它们作为P2Y12受体拮抗剂用于治疗和/或预防外周血管、内脏血管、肝脏血管和肾脏血管、心血管和脑血管疾病或与血小板聚集相关状况的用途，包括人类和其他哺乳动物中的血栓症。
• [EN] SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-PHÉNYL-PYRIDINE SUBSTITUÉS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009125366A1

  公开（公告）日：2009-10-15

  The present invention relates to compounds of formula (I) wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及式(I)化合物，其中R1、R2、R4、R5、Ra、Rb、n、W和Z如申请中所定义，它们的制备以及它们作为P2Y12受体拮抗剂用于治疗和/或预防外周血管、内脏血管、肝脏血管和肾脏血管、心血管和脑血管疾病或与血小板聚集相关的状况的应用，包括人类和其他哺乳动物中的血栓。
• [EN] THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE THIAZOLE ET LEUR UTILISATION COMME ANTAGONISTES DES RÉCEPTEURS P2Y12
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2010122504A1

  公开（公告）日：2010-10-28

  The present invention relates to thiazole derivatives of Formula (I) and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及式(I)的噻唑衍生物及其作为P2Y12受体拮抗剂用于治疗和/或预防外周血管、内脏血管、肝脏血管和肾脏血管、心血管和脑血管疾病或与血小板聚集相关的状况，包括人类和其他哺乳动物中的血栓。
• [EN] CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS<br/>[FR] COMPOSÉS MONO ET SPIROCYCLIQUES CONTENANT DU CYCLOBUTANE ET DE L'AZÉTIDINE EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA V
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089355A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αv-含有整合素的拮抗剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与αv-含有整合素失调相关的疾病、紊乱或病况的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。